Qiagen N.V.
General ticker "QGEN" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $9.6B (TTM average)
Qiagen N.V. does not follow the US Stock Market performance with the rate: -26.7%.
Estimated limits based on current volatility of 1.7%: low 40.90$, high 42.31$
Factors to consider:
- Company pays dividends (irregularly): last record date 2026-07-07, amount 0.35$ (Y0.85%)
- Total employees count: 328 as of 2001
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [43.60$, 60.49$]
- 2026-12-31 to 2027-12-31 estimated range: [45.65$, 63.36$]
Financial Metrics affecting the QGEN estimates:
- Negative: with PPE of 19.8 at the end of fiscal year the price was high
- Positive: Inventory ratio change, % of 0.25 <= 0.80
- Positive: Industry inventory ratio change (median), % of 0.10 <= 0.28
- Positive: Operating profit margin, % of 24.90 > 18.40
- Positive: Return on assets ratio (scaled to [-100,100]) of 6.32 > 6.02
- Negative: Investing cash flow per share per price, % of -3.07 <= -0.60
- Negative: 0.01 < Interest expense per share per price, % of 0.33
Short-term QGEN quotes
Long-term QGEN plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | $1,978.21MM | $2,090.00MM |
| Operating Expenses | $1,880.50MM | $1,569.69MM |
| Operating Income | $97.71MM | $520.31MM |
| Non-Operating Income | $23.44MM | $-30.04MM |
| Interest Expense | $43.84MM | $33.26MM |
| R&D Expense | $193.49MM | $187.52MM |
| Income(Loss) | $121.15MM | $490.26MM |
| Taxes | $37.56MM | $65.39MM |
| Net Income(Loss)* | $83.59MM | $424.88MM |
| Stockholders Equity | $3,567.34MM | $3,778.15MM |
| Inventory | $279.26MM | $301.89MM |
| Assets | $5,689.62MM | $6,295.96MM |
| Operating Cash Flow | $673.55MM | $654.33MM |
| Capital expenditure | $167.17MM | $201.05MM |
| Investing Cash Flow | $-249.23MM | $-305.28MM |
| Financing Cash Flow | $-422.90MM | $-178.98MM |
| Earnings Per Share** | $0.39 | $2.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.